DB:473A

Stock Analysis Report

Executive Summary

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States.


Snowflake Analysis

Excellent balance sheet and fair value.


Similar Companies

Share Price & News

How has Adaptimmune Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 473A's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-8.7%

473A

-4.3%

DE Biotechs

-4.7%

DE Market


1 Year Return

-18.4%

473A

5.5%

DE Biotechs

8.3%

DE Market

Return vs Industry: 473A underperformed the German Biotechs industry which returned 5.5% over the past year.

Return vs Market: 473A underperformed the German Market which returned 8.3% over the past year.


Shareholder returns

473AIndustryMarket
7 Day-8.7%-4.3%-4.7%
30 Day-2.9%-6.7%-4.0%
90 Day333.5%0.4%-1.4%
1 Year-18.4%-18.4%5.8%5.5%11.7%8.3%
3 Year-8.7%-8.7%40.9%39.4%11.4%1.6%
5 Yearn/a10.9%8.6%15.1%-0.7%

Price Volatility Vs. Market

How volatile is Adaptimmune Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Adaptimmune Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 473A (€3.36) is trading below our estimate of fair value (€7.86)

Significantly Below Fair Value: 473A is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 473A is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 473A is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 473A's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 473A is good value based on its PB Ratio (2.5x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Adaptimmune Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

-8.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 473A is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 473A is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 473A is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 473A's revenue (58.6% per year) is forecast to grow faster than the German market (5.1% per year).

High Growth Revenue: 473A's revenue (58.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 473A's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Adaptimmune Therapeutics performed over the past 5 years?

-30.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 473A is currently unprofitable.

Growing Profit Margin: 473A is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 473A is unprofitable, and losses have increased over the past 5 years at a rate of -30.8% per year.

Accelerating Growth: Unable to compare 473A's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 473A is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 473A has a negative Return on Equity (-97.49%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Adaptimmune Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 473A's short term assets ($147.0M) exceed its short term liabilities ($37.4M).

Long Term Liabilities: 473A's short term assets ($147.0M) exceed its long term liabilities ($23.2M).


Debt to Equity History and Analysis

Debt Level: 473A is debt free.

Reducing Debt: 473A had no debt 5 years ago.


Balance Sheet

Inventory Level: 473A has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 473A's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 473A has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 473A has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of -38.3% each year.


Next Steps

Dividend

What is Adaptimmune Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.0%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 473A's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 473A's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 473A's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 473A's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 473A's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.1yrs

Average management tenure


CEO

Ad Rawcliffe (47yo)

0.4yrs

Tenure

US$1,409,387

Compensation

Mr. Adrian Rawcliffe, also known as Ad, has been the Chief Executive Officer and Director of Adaptimmune Therapeutics plc since September 1, 2019. He had been the Chief Financial Officer of Adaptimmune The ...


CEO Compensation Analysis

Compensation vs Market: Ad's total compensation ($USD1.41M) is above average for companies of similar size in the German market ($USD805.15K).

Compensation vs Earnings: Ad's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Adrian Rawcliffe
CEO, Principal Accounting Officer & Director0.4yrsUS$1.41m0.0024% $10.9k
Helen Tayton-Martin
Co-Founder & Chief Business Officer0yrsUS$1.28m0.23% $1.0m
William Bertrand
Chief Operating Officer2.9yrsUS$1.29m0.0028% $12.4k
Rafael Amado
President of Research & Development4.9yrsUS$2.60m0.029% $132.0k
Michael Garone
Interim CFO0.3yrsno datano data
Sébastien Desprez
Vice President of Communications & Investor Relations0yrsno datano data
Lini Pandite
Senior Vice President of Clinical Development4.8yrsno datano data
Trupti Trivedi
Head of Biometrics and Vice President4.4yrsno datano data
P. Dyson
Head of Autoimmune Group4.1yrsno datano data
Phil Bassett
Head of Process Development4.1yrsno datano data

4.1yrs

Average Tenure

54yo

Average Age

Experienced Management: 473A's management team is considered experienced (4.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Adrian Rawcliffe
CEO, Principal Accounting Officer & Director0.4yrsUS$1.41m0.0024% $10.9k
David Mott
Chairman of the Board of Directors3.1yrsUS$225.49k0.51% $2.3m
James Noble
Non-Executive Director0yrsUS$2.64m1.51% $6.8m
Giles F. Kerr
Non-Executive Director3.3yrsUS$199.78kno data
Charles Sigal
Non-Executive Director5yrsUS$186.34k0.047% $211.4k
Barbara Duncan
Non-Executive Director3.7yrsUS$190.46kno data
Ali Behbahani
Non-Executive Director5yrsUS$186.34kno data
Lawrence Alleva
Non-Executive Director4.9yrsUS$179.26k0.015% $67.9k
Tal Zaks
Non-Executive Director3.3yrsUS$193.01kno data
John Furey
Independent Non-Executive Director1.6yrsUS$309.79kno data

3.3yrs

Average Tenure

54yo

Average Age

Experienced Board: 473A's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 473A insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.7%.


Top Shareholders

Company Information

Adaptimmune Therapeutics plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Adaptimmune Therapeutics plc
  • Ticker: 473A
  • Exchange: DB
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$487.778m
  • Listing Market Cap: US$449.390m
  • Shares outstanding: 130.07m
  • Website: https://www.adaptimmune.com

Number of Employees


Location

  • Adaptimmune Therapeutics plc
  • 60 Jubilee Avenue
  • Milton Park
  • Abingdon
  • Oxfordshire
  • OX14 4RX
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ADAPNasdaqGS (Nasdaq Global Select)YesADS EACH REPR ORD SHS (SPONS)USUSDMay 2015
473ADB (Deutsche Boerse AG)YesADS EACH REPR ORD SHS (SPONS)DEEURMay 2015

Biography

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company’s specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune’s PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to bring new stem-cell derived allogeneic T-Cell therapies to people with cancer. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/24 23:24
End of Day Share Price2020/02/24 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.